BAX vs INVA: fair value comparison
Baxter International Inc. and Innoviva, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BAX currently sits closer to the top of our ranking by discount to fair value. INVA carries the stronger quality grade.
| BAX | INVA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $24.35 | $20.78 |
| 12-month range | $15.80–$28.35 | $17.57–$24.24 |
| Rank by discount to fair value | #40 of 108 Healthcare | #43 of 108 Healthcare |
| Quality grade | D | A |
| Leverage | High | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: BAX fair value analysis · INVA fair value analysis